Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48658 | 0.78 | CES2 (0.42) | ALDH1A1SMN1; SMN2KIF11XDHERN1 | |
| SCHEMBL1811153 | 0.76 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2KIF11XDHERN1 | |
| SCHEMBL6738427 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KIF11XDHERN1 | |
| SCHEMBL29957050 | 0.75 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2KIF11ERN1 | |
| SCHEMBL4547667 | 0.74 | HDAC1 (0.40) | HDAC1HDAC6ALDH1A1SMN1; SMN2KIF11 | |
| SCHEMBL14194018 | 0.74 | ALDH1A1 (0.36) | HDAC1HDAC6ALDH1A1CA1CA2 | |
| SCHEMBL1922945 | 0.74 | ERN1 (0.52) | ALDH1A1SMN1; SMN2XDHERN1 | |
| SCHEMBL16584916 | 0.74 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2KIF11XDHERN1 | |
| SCHEMBL6735248 | 0.74 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2KIF11XDHERN1 | |
| SCHEMBL8280034 | 0.73 | ALDH1A1 (0.50) | HDAC1HDAC6ALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2013175-A1 | p38 MAP KINASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007129040-A1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007129040-A1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
| EP-0930298-B1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2002-12-18 | — | — | EP | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | HDAC1 709/4885HDAC6 2466/4885ALDH1A1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.